Cancer cells rewire their metabolic programs in response to changes in the tumor microenvironment and in oncogenic signals such as an activating KRAS mutation [31] while AMG510 is a KRAS inhibitor targeting G12C-mutant KRAS. This evidence concerns the gene KRAS and neoplasm.